LLY

916.01

+0.63%↑

JNJ

238.16

+0.01%↑

ABBV

207.4

-2.1%↓

NVS

148.81

-1.55%↓

AZN

188.48

-0.11%↓

LLY

916.01

+0.63%↑

JNJ

238.16

+0.01%↑

ABBV

207.4

-2.1%↓

NVS

148.81

-1.55%↓

AZN

188.48

-0.11%↓

LLY

916.01

+0.63%↑

JNJ

238.16

+0.01%↑

ABBV

207.4

-2.1%↓

NVS

148.81

-1.55%↓

AZN

188.48

-0.11%↓

LLY

916.01

+0.63%↑

JNJ

238.16

+0.01%↑

ABBV

207.4

-2.1%↓

NVS

148.81

-1.55%↓

AZN

188.48

-0.11%↓

LLY

916.01

+0.63%↑

JNJ

238.16

+0.01%↑

ABBV

207.4

-2.1%↓

NVS

148.81

-1.55%↓

AZN

188.48

-0.11%↓

Home・Akciju saraksts・Cogent Biosciences Inc

Cogent Biosciences Inc

Atvērts

34.05 -1.45

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

34.25

Max

34.98

Galvenie mērījumi
By Trading Economics
Ienākumi	-22M -102M
EPS	-0.5
Darbinieki	258
EBITDA	-30M -109M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+48.36% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	184M 5.8B
Iepriekšējā atvēršanas cena	35.5
Iepriekšējā slēgšanas cena	34.05

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

4.88 / 5.87 Atbalsts un pretestība

Cogent Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 18. marts 22:51 UTC

Peļņas

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

2026. g. 18. marts 21:40 UTC

Iegādes, apvienošanās, pārņemšana

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

2026. g. 18. marts 20:31 UTC

Peļņas

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

2026. g. 18. marts 23:49 UTC

Tirgus saruna

Galvenie ziņu notikumi

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

2026. g. 18. marts 23:31 UTC

Tirgus saruna

Gold Rises on Likely Technical Recovery -- Market Talk

2026. g. 18. marts 22:49 UTC

Tirgus saruna

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

2026. g. 18. marts 22:41 UTC

Tirgus saruna

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

2026. g. 18. marts 22:36 UTC

Peļņas

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

2026. g. 18. marts 22:24 UTC

Peļņas

AIA Group Announces New Share Buyback of $1.7B >1299.HK

2026. g. 18. marts 22:23 UTC

Peļņas

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

2026. g. 18. marts 22:23 UTC

Peļņas

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

2026. g. 18. marts 21:58 UTC

Peļņas

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

2026. g. 18. marts 21:55 UTC

Tirgus saruna

Peļņas

Global Equities Roundup: Market Talk

2026. g. 18. marts 21:55 UTC

Tirgus saruna

Peļņas

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

2026. g. 18. marts 21:40 UTC

Tirgus saruna

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

2026. g. 18. marts 21:16 UTC

Tirgus saruna

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

2026. g. 18. marts 21:00 UTC

Galvenie ziņu notikumi

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

2026. g. 18. marts 20:58 UTC

Peļņas

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

2026. g. 18. marts 20:41 UTC

Peļņas

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

2026. g. 18. marts 20:29 UTC

Peļņas

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

2026. g. 18. marts 20:25 UTC

Peļņas

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

2026. g. 18. marts 20:17 UTC

Peļņas

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

2026. g. 18. marts 20:14 UTC

Tirgus saruna

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

2026. g. 18. marts 20:09 UTC

Peļņas

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

2026. g. 18. marts 20:07 UTC

Peļņas

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

2026. g. 18. marts 20:06 UTC

Peļņas

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

2026. g. 18. marts 20:04 UTC

Peļņas

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

2026. g. 18. marts 20:04 UTC

Peļņas

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

2026. g. 18. marts 20:04 UTC

Peļņas

Micron Technology Sees 3Q Gross Margin About 81% >MU

2026. g. 18. marts 20:03 UTC

Peļņas

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Salīdzinājums

Cenas izmaiņa

Cogent Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

48.36% augšup

Prognoze 12 mēnešiem

Vidējais 52.55 USD 48.36%

Augstākais 64 USD

Zemākais 35 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

12 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 12 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

4.88 / 5.87Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.